Zevenbergen Capital Investments LLC Has $35.62 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Zevenbergen Capital Investments LLC increased its holdings in DexCom, Inc. by 34.7%, holding 521,553 shares valued at $35.62 million as of its latest SEC filing.
• Several brokerages have raised their price targets for DexCom stock, with Piper Sandler setting the highest target at $100.00, while the average rating stands at "Moderate Buy."
• DexCom reported earnings of $0.48 per share for the last quarter, exceeding estimates, and experienced a 15.2% year-over-year increase in revenue.

Zevenbergen Capital Investments LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 34.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 521,553 shares of the medical device company's stock after acquiring an additional 134,385 shares during the quarter. DexCom accounts for about 0.9% of Zevenbergen Capital Investments LLC's investment portfolio, making the stock its 29th largest holding. Zevenbergen Capital Investments LLC owned 0.13% of DexCom worth $35,617,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC boosted its position in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the period. Private Trust Co. NA boosted its position in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares during the period. Farther Finance Advisors LLC boosted its position in DexCom by 29.3% during the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after acquiring an additional 702 shares during the period. Dynamic Advisor Solutions LLC boosted its position in DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after acquiring an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC boosted its position in DexCom by 944.5% during the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock worth $220,000 after acquiring an additional 2,909 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on DXCM. Morgan Stanley raised their price objective on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Piper Sandler raised their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Barclays raised their price target on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $106.00 price target on shares of DexCom in a research note on Friday, August 1st. Finally, Raymond James Financial raised their price target on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average price target of $99.89.

DexCom Stock Performance

DXCM opened at $78.86 on Friday. The firm has a market capitalization of $30.92 billion, a P/E ratio of 54.76, a price-to-earnings-growth ratio of 1.65 and a beta of 1.43. The stock's 50 day moving average price is $83.68 and its two-hundred day moving average price is $80.32. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The company's revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,656 shares of company stock worth $2,412,191. Corporate insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.